Trevi Therapeutics Announces Third Quarter Corporate Update
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering clinical-stage biopharmaceutical company, is set to host a conference call and audio webcast to provide its latest corporate updates and financial results for the quarter that ended recently. This significant event is scheduled to take place on November 6, during the late afternoon hours.
Conference Call Details
The live conference call will start at 4:30 p.m. ET. Interested participants can join by dialing either (877) 870 4263 for domestic calls or (412) 317 0790 for international calls. No code will be necessary for access to the call, ensuring participants can easily connect.
Webcast Accessibility
For those who prefer to listen online, Trevi Therapeutics will be providing a live audio webcast situated in the 'Investors & News' section of its official website. An archived replay of the call will also be available for 30 days after the event, allowing stakeholders to catch up on the discussion at their convenience.
About Trevi Therapeutics and Haduvio™
Trevi Therapeutics focuses on the development of the investigational therapy known as Haduvio™ (oral nalbuphine ER). This innovative treatment is engineered to address chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). By acting on both central and peripheral cough reflexes, Haduvio™ serves as a kappa agonist and a mu antagonist, implicating its unique role in managing cough sensitivity.
Chronic Cough: A Critical Health Concern
The burden of chronic cough is substantial, significantly impacting patients' social and emotional wellbeing, and exacerbating physical health issues. In patients with IPF, chronic cough may further complicate their condition, increasing the risks associated with disease progression and leading to dire outcomes like lung transplants. As of now, there are no approved therapies specifically targeting chronic cough in IPF, and existing treatments often fall short of providing meaningful relief. Haduvio’s recognition extends beyond IPF, as it ventures into the realm of RCC, a condition for which there are currently no authorized treatments in the U.S.
Future Prospects for Haduvio™
Trevi Therapeutics is making strides in proposing Haduvio as the official trade name for oral nalbuphine ER. While the therapy's efficacy and safety are still under evaluation, its potential to address chronic cough presents a beacon of hope for many patients. Trevi is dedicated to bridging the existing treatment gap and improving quality of life for those afflicted with chronic cough.
Keeping Informed and Engaged
Trevi Therapeutics encourages those interested to explore their website for further details and insights. Staying informed about advancements in the company’s therapeutic developments will be essential for investors and affected patients alike. As the company continues its commitment to impacting lives positively, public involvement and awareness remain vital.
Frequently Asked Questions
What is the date of Trevi Therapeutics' upcoming conference call?
The conference call is scheduled for November 6, taking place at 4:30 p.m. ET.
How can I join the Trevi Therapeutics conference call?
Participants can join the call by calling (877) 870 4263 for domestic access or (412) 317 0790 for international access.
What therapy is Trevi Therapeutics developing?
Trevi Therapeutics is developing Haduvio™, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.
Is Haduvio™ currently approved for use?
Haduvio™ is still under development and has not yet been evaluated for its safety and efficacy by regulatory authorities.
Where can I find more information about Trevi Therapeutics?
More information can be found on Trevi Therapeutics' official website.
